– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support, and a safety switch – – Preliminary clinical data from a case study featured in ASH abstract shows complete response maintained in Dose Cohort 1 patient following completion of four 28-day cycles of CNTY-101 in Phase 1 ELiPSE-1 trial, the two most recent of which did not include lymphodepletion – – CNTY-101 well tolerated – – Additional data from Dose Cohort 1 patients, as well as preliminary data from Dose Cohort 2, to be featured in ASH presentation – PHILADELPHIA, Nov.

-CNTY-101是第一个经过6个精确基因编辑的候选细胞治疗产品，包括CD19-CAR，Allo-Evasion™技术，IL-15细胞因子支持和安全开关-来自ASH摘要中的案例研究的初步临床数据显示，在第1阶段完成CNTY-101的4个28天周期后，剂量组1患者维持完全反应ELiPSE-1试验，其中最近的两个不包括淋巴细胞清除-CNTY-101耐受性良好-来自剂量队列1患者的其他数据，以及来自剂量队列2的初步数据，将在ASH报告中介绍-费城，十一月。

02, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immune-oncology, today announced the upcoming presentation of initial data from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas.

022023（GLOBE NEWSWIRE）-Century Therapeutics，Inc。（纳斯达克股票代码：IPSC）是一家在免疫肿瘤学领域开发诱导多能干细胞（IPSC）衍生细胞疗法的创新生物技术公司，今天宣布即将提交初始数据来自其正在进行的CNTY-101在复发/难治性CD19阳性B细胞淋巴瘤中的首次人体内1期ELiPSE-1试验。

The data, which support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits, will be featured during a poster session at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023 in San Diego. CNTY-101 is the Company’s first allogeneic cell therapy product candidate engineered with multiple complementary functionalities designed to enhance its product profile.

这些数据支持通过同种异体逃避实现汽车油墨多剂量策略的潜力™ 编辑，将在2023年12月9日至12日在圣地亚哥举行的第65届美国血液学会（ASH）年会和博览会的海报会议上展出。CNTY-101是该公司第一个设计有多种互补功能的同种异体细胞治疗产品候选产品，旨在增强其产品特性。

These features include a CD19 CAR for tumor targeting, IL-15 support for enhanced persistence, Allo-Evasion™ technology to prevent host rejection and enhance persistence, and a safety switch to provide the option to eliminate the drug product if ever necessary. A copy of the abstract, which highlights a case study of a patien.

这些特征包括用于肿瘤靶向的CD19 CAR，用于增强持久性的IL-15支持，同种异体逃避™ 技术，以防止主机拒绝和增强持久性，并提供安全开关，以提供必要时消除药品的选择。摘要的副本，突出了一个病人的案例研究。